Back HIV/AIDS HIV/AIDS Topics HIV Treatment

Coverage of HIV Drug Therapy Glasgow 2016

HIVandHepatitis.com coverage of the 2016 International Congress on Drug Therapy in HIV Infection, held  October 23-26, 2016, in Glasgow, Scotland.

Conference highlights include new antiretroviral therapies and strategies, HIV prevention, HIV-related comorbidities, and expanding access to treatment.

Full listing of coverage by topic

HIV Drug Therapy 2016 website

11/4/16

alt

IDWeek 2016: Dolutegravir Regimen Works Better than Atazanavir in Clinical Trial for Women

A once-daily regimen containing the potent HIV integrase inhibitor dolutegravir worked better than an older atazanavir-containing regimen -- with higher rates of viral suppression both overall and across race subgroups -- in the ARIA trial, one of the few antiretroviral therapy studies to enroll only women, according to a presentation at IDWeek last week in New Orleans.

alt

Read more:

HIV Glasgow: 2-Drug HIV Therapy Just as Effective as Standard 3-Drug Therapy

Simplification of antiretroviral treatment to a boosted protease inhibitor and the nucleoside analog lamivudine -- a dual regimen -- is highly effective for people switching from a stable 3-drug regimen, researchers reported this week at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow).

alt

Read more:

HIV Glasgow: Dolutegravir and Central Nervous System Side-Effects -- Abacavir, Older Age Increase the Risk

Insomnia, dizziness, headache, and other central nervous system (CNS) side effects are occurring more frequently with everyday use of dolutegravir than clinical trials had suggested, and are most likely to occur among women, people over age 60, and people starting abacavir at the same time, a German research group reported at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow) this week.

alt

Read more:

HIVR4P 2016: More Viral Suppression Needed to Reduce HIV Infections Among Gay Men

HIV suppression on antiretroviral therapy (ART) would need to increase substantially among men who have sex with men in order to take advantage of "treatment as prevention" to reduce the rate of new HIV infections, according to a mathematical modeling study presented at the HIV Research for Prevention conference (HIVR4P 2016) taking place this week in Chicago.

alt

Read more:

IDWeek 2016: Ibalizumab Monoclonal Antibody Looks Promising for HIV Patients Left Behind

Ibalizumab, an experimental antiretroviral agent that works differently than existing HIV drugs, demonstrated promising safety and antiviral activity in a small Phase 3 study of people with highly drug-resistant virus, according to a report at the IDWeek conference this week in New Orleans. If confirmed in larger studies, this could be good news for HIV patients who cannot be successfully treated using available therapies.

alt

Read more:

Researchers Observe Sustained Remission in Monkeys with HIV-Like Virus

Researchers have induced sustained remission of simian immune deficiency virus (SIV), a relative of HIV, in macaque monkeys treated with antiretroviral therapy (ART) and an antibody-based therapy used to treat inflammatory bowel disease, according to a report in the October 14 edition of Science. The monkeys not only had undetectable viral load for up to nearly 2 years after stopping treatment, but they also showed replenishment of key immune cells in the gut.

alt

Read more: